BSEM Company Profile and Key Details

BioStem Technologies, Inc. (NASDAQ:BSEM) closed at $4.17 USD, losing -$0.04 (-0.83%) from the previous close of $4.21. The stock is currently mid-range between its 52-week high and low $2.25 and $8.40. With a market capitalization of about $70.91 million, BioStem Technologies, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.26). Key stats such as the average daily volume over the past year has been around 81.70 thousand shares, in line with its 52-week average. Headquartered in Fort Lauderdale, FL, BioStem Technologies, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jason Matuszewski, the company employs approximately 73 people and listed since March 17, 2015. BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.

Average 10-day trading volume of 141.99 thousand shares is significantly above the 3-month average of 80.96 thousand, indicating heightened recent market interest.

BioStem Technologies, Inc. earnings surprise history is a mixed track record. The quarter that ended August 12, 2026, missed forecasts by 4.0%. The prior quarter beat by 85.71%. Over the last six quarters, Apple has recorded several small beats. These include -45.6% in April 14, 2025.

BioStem Technologies, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.34. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that BioStem Technologies, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.24%, with price expected at $4.17 by September 23, 2026, within a range of $3.82 to $4.52 3-Month Outlook: Projected fall of -23.92%, reaching $3.18 by December 08, 2026, with a range of $2.74 to $3.58. 1-Year Outlook: Projected gain of 25.36%, with price at $5.24 by September 10, 2027, within a range of $0.00 to $5.45.

Valuation shows BioStem Technologies, Inc. trading at a premium to the broader market with a P/E of -2.52. Our AI forecast model points to short-term weakness (-0.24% over two weeks), a medium-term fall (-23.92% over three months), and a longer-term gain (25.36% over one year), with expected trading ranges indicating moderate volatility.

BioStem Technologies, Inc. trades at a P/E ratio of -2.52, slightly below the S&P 500 average, with a price-to-sales ratio of -1.18 and a price-to-book ratio of 2.63 suggesting the stock is closer to book value. The P/FCF stands at -8.07, also below market averages.